|Application ||WB, IF, E|
|Other Accession||Q4V8F5, Q8R0L9, Q7SY21, Q5EAE2, Q66IZ5, Q6PGT0, NP_006345.1, NP_597814.1|
|Predicted||Xenopus, Bovine, Zebrafish, Mouse, Rat|
|Calculated MW||48902 Da|
|Antigen Region||386-414 aa|
|Other Names||Transcriptional adapter 3, ADA3 homolog, hADA3, STAF54, Transcriptional adapter 3-like, ADA3-like protein, TADA3, ADA3, TADA3L|
|Target/Specificity||This TADA3L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 386-414 amino acids from the C-terminal region of human TADA3L.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Precautions||TADA3L Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Functions as a component of the PCAF complex. The PCAF complex is capable of efficiently acetylating histones in a nucleosomal context. The PCAF complex could be considered as the human version of the yeast SAGA complex. Also known as a coactivator for p53/TP53-dependent transcriptional activation. Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4.|
|Tissue Location||Ubiquitously expressed.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Many DNA-binding transcriptional activator proteins enhance the initiation rate of RNA polymerase II-mediated gene transcription by interacting functionally with the general transcription machinery bound at the basal promoter. Adaptor proteins are usually required for this activation, possibly to acetylate and destabilize nucleosomes, thereby relieving chromatin constraints at the promoter. The protein encoded by this gene is a transcriptional activator adaptor and has been found to be part of the PCAF histone acetylase complex. In addition, it associates with the tumor suppressor protein p53 and is required for full activity of p53 and p53-mediated apoptosis. At least four alternatively spliced variants have been found for this gene, but the full-length nature of some variants has not been determined. [provided by RefSeq].
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Li, C.W., et al. Nucleic Acids Res. 38(16):5291-5303(2010)
Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
Hu, Y., et al. Cancer Invest. 27(3):298-306(2009)
Wang, Y.L., et al. J. Biol. Chem. 283(49):33808-33815(2008)
If you have any additional inquiries please email technical services at email@example.com.